ESR1 and ductal breast carcinoma in situ: Moreover, adjuvant tamoxifen treatment after excision of breast ductal carcinoma in situ (DCIS), a form of noninvasive breast carcinoma, has been shown to reduce recurrent risk, even in lesions without ER expression [8].